Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Apr 1;48(4):395-400.
doi: 10.1097/DSS.0000000000003401.

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Tanat Yongpisarn  1 , Rachel Rigo  2 , Kira Minkis  2
Affiliations
Meta-Analysis

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Tanat Yongpisarn et al. Dermatol Surg. .

Abstract

Background: Although surgery is the treatment of choice for Bowen disease (BD) and cutaneous squamous cell carcinoma (cSCC), nonsurgical treatments such as photodynamic therapy (PDT) may be preferred for select tumors. Previous meta-analysis have failed to gather strong evidence to recommend PDT.

Objective: This study evaluates the effectiveness of PDT in the treatment of cSCC and BD for clearance rate (CR) after 1 year.

Methods: A literature search of studies of biopsy-proven BD and cSCC treated with PDT was performed. Pooled CRs were estimated. Subgroup analyses were performed based on follow-up, treatment regimen, lesion size, and site.

Results: Forty-three studies were included, enrolling 1943 BD lesions and 282 SCC lesions. Pooled CRs for BD and SCC were 76% (95% CI: 71%-80%; I2 = 78.9%) and 51% (95% CI: 35%-66%; I2 = 85.7%), respectively.

Conclusion: Our findings support the selective use of PDT for BD; however, patients should be advised of potential for recurrence. Although PDT can be used for certain cases of cSCC, the high rate of treatment failure necessitates close surveillance for residual or recurrent disease. Further studies are needed to justify the usage of PDT in the treatment of BD and cSCC.

PubMed Disclaimer

References

    1. Gracia-Cazaña T, Mascaraque M, Salazar N, Vera-Álvarez J, et al. Photodynamic therapy: influence of clinical and procedure variables on treatment response in basal cell carcinoma and bowen disease. Acta Derm Venereol 2018;98:116–8.
    1. Hambly R, Mansoor N, Quinlan C, Shah Z, et al. Topical photodynamic therapy for primary Bowen disease and basal cell carcinoma: optimizing patient selection. Br J Dermatol 2017;177:e55–e57.
    1. Haddad R, Nesher E, Weiss J, Skornick Y, et al. Photodynamic therapy for Bowen's disease and squamous cell carcinoma of the skin. Photodiagnosis Photodyn Ther 2004;1:225–30.
    1. Xu S, Wang X, Xu W, Xia Y, et al. Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin Med J (Engl) 2002;115:1141–5.
    1. Morton C, Horn M, Leman J, Tack B, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006;142:729–35.

MeSH terms

Substances